Log in

NASDAQ:SYNH - Syneos Health Stock Price, Forecast & News

$63.99
+0.13 (+0.20 %)
(As of 01/20/2020 01:27 AM ET)
Today's Range
$63.32
Now: $63.99
$64.44
50-Day Range
$54.20
MA: $58.04
$63.99
52-Week Range
$36.72
Now: $63.99
$64.72
Volume344,392 shs
Average Volume453,669 shs
Market Capitalization$6.64 billion
P/E Ratio78.04
Dividend YieldN/A
Beta1.52
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SYNH
CUSIPN/A
Phone919-876-9300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.39 billion
Cash Flow$5.32 per share
Book Value$27.67 per share

Profitability

Net Income$24.28 million

Miscellaneous

Employees24,000
Market Cap$6.64 billion
Next Earnings Date3/16/2020 (Estimated)
OptionableOptionable

Receive SYNH News and Ratings via Email

Sign-up to receive the latest news and ratings for SYNH and its competitors with MarketBeat's FREE daily newsletter.


Syneos Health (NASDAQ:SYNH) Frequently Asked Questions

What is Syneos Health's stock symbol?

Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."

How were Syneos Health's earnings last quarter?

Syneos Health Inc (NASDAQ:SYNH) released its quarterly earnings results on Thursday, October, 31st. The company reported $0.87 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.82 by $0.05. The business earned $1.18 billion during the quarter, compared to analysts' expectations of $1.18 billion. Syneos Health had a return on equity of 10.13% and a net margin of 1.86%. The firm's revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period last year, the firm posted $0.75 EPS. View Syneos Health's Earnings History.

When is Syneos Health's next earnings date?

Syneos Health is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Syneos Health.

What guidance has Syneos Health issued on next quarter's earnings?

Syneos Health issued an update on its FY 2020 After-Hours earnings guidance on Wednesday, January, 15th. The company provided EPS guidance of 3.58-3.78 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.59. The company issued revenue guidance of $4.88-5 billion, compared to the consensus revenue estimate of $4.94 billion.

What price target have analysts set for SYNH?

10 Wall Street analysts have issued 1-year target prices for Syneos Health's shares. Their forecasts range from $48.00 to $75.00. On average, they anticipate Syneos Health's stock price to reach $64.50 in the next year. This suggests a possible upside of 0.8% from the stock's current price. View Analyst Price Targets for Syneos Health.

What is the consensus analysts' recommendation for Syneos Health?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syneos Health.

Has Syneos Health been receiving favorable news coverage?

Media stories about SYNH stock have been trending positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Syneos Health earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Syneos Health.

Who are some of Syneos Health's key competitors?

What other stocks do shareholders of Syneos Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include NVIDIA (NVDA), Icon (ICLR), Jazz Pharmaceuticals (JAZZ), Netflix (NFLX), Skyworks Solutions (SWKS), Alibaba Group (BABA), Square (SQ), Constellation Brands (STZ), AT&T (T) and UnitedHealth Group (UNH).

Who are Syneos Health's key executives?

Syneos Health's management team includes the folowing people:
  • Mr. Alistair Macdonald, CEO & Director (Age 49)
  • Mr. Jason M. Meggs, Chief Financial Officer (Age 43)
  • Mr. Jonathan Olefson, Gen. Counsel & Corp. Sec. (Age 43)
  • Mr. Michael Adam Bell, Consultant (Age 63)
  • Mr. Robert Parks, Exec. VP & Chief Accounting Officer

Who are Syneos Health's major shareholders?

Syneos Health's stock is owned by many different of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (0.63%), Hennessy Advisors Inc. (0.26%), Bowling Portfolio Management LLC (0.03%), Louisiana State Employees Retirement System (0.01%), State of Alaska Department of Revenue (0.01%) and Nisa Investment Advisors LLC (0.01%). Company insiders that own Syneos Health stock include Alistair Macdonald, Christopher L Gaenzle, H Lee Equity Fund Vi Thomas, Jason M Meggs and Jonathan Olefson. View Institutional Ownership Trends for Syneos Health.

Which institutional investors are selling Syneos Health stock?

SYNH stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Nisa Investment Advisors LLC, State of Alaska Department of Revenue and First Hawaiian Bank. View Insider Buying and Selling for Syneos Health.

Which institutional investors are buying Syneos Health stock?

SYNH stock was bought by a variety of institutional investors in the last quarter, including Hennessy Advisors Inc., Bowling Portfolio Management LLC, Allred Capital Management LLC, Alpha Windward LLC and Louisiana State Employees Retirement System. Company insiders that have bought Syneos Health stock in the last two years include Jason M Meggs and Jonathan Olefson. View Insider Buying and Selling for Syneos Health.

How do I buy shares of Syneos Health?

Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Syneos Health's stock price today?

One share of SYNH stock can currently be purchased for approximately $63.99.

How big of a company is Syneos Health?

Syneos Health has a market capitalization of $6.64 billion and generates $4.39 billion in revenue each year. The company earns $24.28 million in net income (profit) each year or $2.62 on an earnings per share basis. Syneos Health employs 24,000 workers across the globe.View Additional Information About Syneos Health.

What is Syneos Health's official website?

The official website for Syneos Health is http://www.syneoshealth.com/.

How can I contact Syneos Health?

Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The company can be reached via phone at 919-876-9300 or via email at [email protected]


MarketBeat Community Rating for Syneos Health (NASDAQ SYNH)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  490 (Vote Outperform)
Underperform Votes:  395 (Vote Underperform)
Total Votes:  885
MarketBeat's community ratings are surveys of what our community members think about Syneos Health and other stocks. Vote "Outperform" if you believe SYNH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYNH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel